CVKD

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

S-8 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005Cadrenal has received strong interest from potential strategic partnersCadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) ("Cadrenal" or the "Company"), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.w

S-8 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in the 28th Annual H.C. Wainwright Global Investment Conference, September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company will be available on demand through the conference portal beginning Friday, September 11, 2026, at 7:00 a.m. ET. A copy of the slide presentation will be available on the investor relations section of the Cadrenal website at h

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026. During the meeting, Cadrenal and the FDA aligned on key aspects of th

10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise. "The second quarter and subsequent weeks marked an important milestone for Cadrenal," said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. "Our obje

SCHEDULE 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

DEFA14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

DEF 14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injuryDual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)Addresses High-Value Gap in the Acute Care Market –First-in-class positioning in the $1 billion+ U.S. CSA-AKI market following the recent discontinuation of a competitor's late-stage Phase 3 clinical trial for lack of efficacyGlobal Partnering Potential – Levera

PRE 14A - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarinRecently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of

EFFECT - Cadrenal Therapeutics, Inc. (0001937993) (Filer)